Rigel Pharmaceuticals - RIGL Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares.
View RIGL analyst ratings or view top-rated stocks.

7 brokers have issued twelve-month target prices for Rigel Pharmaceuticals' shares. Their RIGL share price forecasts range from $1.00 to $15.00. On average, they anticipate the company's stock price to reach $3.96 in the next twelve months. This suggests a possible upside of 427.1% from the stock's current price.
View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts.

Rigel Pharmaceuticals' stock was trading at $2.65 at the start of the year. Since then, RIGL shares have decreased by 71.7% and is now trading at $0.7509.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RIGL earnings forecast.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.02. The biotechnology company had revenue of $21.54 million for the quarter, compared to analysts' expectations of $24.16 million. Rigel Pharmaceuticals had a negative net margin of 92.44% and a negative trailing twelve-month return on equity of 2,419.00%. During the same quarter in the previous year, the business posted ($0.08) EPS.

6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Rigel Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.36%), Vanguard Group Inc. (6.91%), State Street Corp (2.24%), Armistice Capital LLC (2.00%), Jacobs Levy Equity Management Inc. (1.71%) and Assenagon Asset Management S.A. (1.55%).
View institutional ownership trends.

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RIGL stock can currently be purchased for approximately $0.75.

Rigel Pharmaceuticals (NASDAQ:RIGL) has a market capitalization of $129.79 million and generates $149.24 million in revenue each year. The biotechnology company earns $-17,910,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

The company employs 165 workers across the globe.

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rigel.com. The biotechnology company can be reached via phone at (650) 624-1100, via email at ir@rigel.com, or via fax at 650-624-1101.